Schonfeld Strategic Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.52M	Buy	318,177 +21,746	+7%	+$139K	0.01%	942
2026 Q1	$1.72M	Buy	296,431 +61,708	+26%	+$409K	0.01%	884
2025 Q4	$1.84M	Sell	234,723 -69,781	-23%	-$549K	0.01%	904
2025 Q3	$2.48M	Sell	304,504 -84,562	-22%	-$562K	0.01%	923
2025 Q2	$1.82M	Sell	389,066 -211,101	-35%	-$967K	0.01%	1037
2025 Q1	$3.29M	Buy	600,167 +497,167	+483%	+$2.01M	0.02%	703
2024 Q4	$349K	Sell	103,000 -69,327	-40%	-$223K	﹤0.01%	1549
2024 Q3	$491K	Sell	172,327 -163,720	-49%	-$420K	﹤0.01%	1442
2024 Q2	$756K	Buy	336,047 +45,549	+16%	+$91.8K	﹤0.01%	1322
2024 Q1	$642K	Buy	+290,498	New	+$752K	﹤0.01%	1386
2023 Q3	–	Sell	-25,800	Closed	-$67.6K	–	2362
2023 Q2	$67.6K	Buy	+25,800	New	+$65.7K	﹤0.01%	1783
2022 Q2	–	Sell	-12,500	Closed	-$32K	–	3057
2022 Q1	$32K	Buy	+12,500	New	+$30.5K	﹤0.01%	2374

Other funds holding XERS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Schonfeld Strategic Advisors's XERS Position: Q2 2026 in Review

Schonfeld Strategic Advisors increased its Xeris Biopharma Holdings (XERS) stake by 7.3% in Q2 2026, buying an estimated $139K and bringing the position to 318,177 shares worth $2.52M. The position accounts for 0.01% of the portfolio, ranked #942.

Schonfeld Strategic Advisors first reported a position in XERS in Q1 2022 and has held it in 12 quarters since. The position peaked at $3.29M in Q1 2025. 240 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

Schonfeld Strategic Advisors held 318,177 shares of Xeris Biopharma Holdings worth $2.52M as of Q2 2026.
Schonfeld Strategic Advisors bought 21,746 Xeris Biopharma Holdings shares in Q2 2026, an estimated $139K.
Xeris Biopharma Holdings made up 0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #942 holding.
Schonfeld Strategic Advisors first reported a position in Xeris Biopharma Holdings in Q1 2022 and has held it in 12 quarters since.
Schonfeld Strategic Advisors's Xeris Biopharma Holdings position peaked at $3.29M in Q1 2025.
240 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.